Immupharma PLC Notice of AGM and posting of Report & Accounts (4700A)
02 Junio 2021 - 1:00AM
UK Regulatory
TIDMIMM
RNS Number : 4700A
Immupharma PLC
02 June 2021
RNS: RELEASE 2 JUNE 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notice of AGM and posting of Report & Accounts
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), the
specialist drug discovery and development company, confirms that
the Annual Report and Accounts for the year ended 31 December 2020,
and the Notice of Annual General Meeting has been posted to
shareholders.
These documents are available, in electronic form, for download
on the Company's website www.immupharma.co.uk .
ImmuPharma's Annual General Meeting (AGM) will be held on
Monday, 28 June 2021 @ 10.30am (BST) at: 25 Wilton Road, Victoria,
London SW1V 1LW.
Government guidance in the UK relating to COVID-19 continues to
place restrictions on public gatherings, so shareholders will not
be permitted to attend the AGM in person. The AGM will therefore be
held with the minimum attendance necessary to form a quorum (which
will be facilitated by the Company).
In light of those measures, we strongly encourage you to
consider ensuring your vote is counted by submission of the proxy
by post. Please complete the paper proxy that accompanies this
notice and return it to the Company's Registrar, Computershare
Investor Services plc, The Pavilions, Bridgwater Road, Bristol,
BS99 6ZY. All proxy forms must be received by no later than 48
hours prior to the AGM, being 10:30am on Thursday 24 June 2021.
Investor Meet Company | Virtual Participation
In order to ensure that shareholders are able to follow the
proceedings of the AGM, the Company will provide a live broadcast
of the AGM through the Investor Meet Company ("IMC") platform.
However, shareholders will not be able to vote online during the
AGM and are therefore urged to submit their votes via proxy as
early as possible. Shareholders are also invited to submit written
questions for the Board to consider. Questions can be pre-submitted
in advance of the AGM via the IMC platform up to 09:00am on 25 June
2021, being the working day before the AGM, or via the IMC platform
at any time during the AGM itself. The Board will respond to key
questions during the meeting and will provide such answers via the
IMC platform thereafter. Shareholders who wish to attend the AGM
online should register for the event in advance via the following
link:
https://www.investormeetcompany.com/immupharma-plc/register-investor
Ends
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase 3 for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase 3 trial for Lupuzor(TM) and commercialise in
the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFBMITMTTMBPB
(END) Dow Jones Newswires
June 02, 2021 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024